BioAtla Overview
DCF fair value estimate for BioAtla: $-0.67.
Get informed when a big investor buys or sells
+ Follow$-0.67
Overvalued by 138.9% based on the discounted cash flow analysis.
BioAtla posts a DCF fair value of $-0.67. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
Markets price BCAB on many factors — sentiment, liquidity, and near-term news — while DCF focuses on long-run cash flows. The current fair-value estimate of $-0.67 sits 138.9% below the live price. Large gaps can highlight opportunity or model risk; the charts on this page help you see how the estimate has moved over time.
Context for BCAB's DCF fair value usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; BioAtla's other metric pages and overview cover the third.
Judging BioAtla against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in DCF fair value easier to interpret. Start with $-0.67 here, then scan peer and history charts to see if the gap is persistent.
